Eltrombopag, a thrombopoietin receptor agonist that stimulates the proliferation of megakaryocytes [30], may be a candidate small molecule for immunotherapy if it can also act as a TCR agonist to promote anti-tumor immunity. This evidence concerns the gene MPL and neoplasm.